Cartilage repair/regeneration market size in 2026 is estimated at USD 1.96 billion, growing from 2025 value of USD 1.73 billion with 2031 projections showing USD 3.69 billion, growing at 13.44% CAGR over 2026-2031. This report is Segmented by Types of Cartilage (Hyaline, and More), Treatment Modality (Cell-Based, Non-cell-based/Cell-free), Treatment Type (Palliative, and More), Surgical Technique (ACI, and More), Application Site (Knee, Hip, and More), End User (Hospitals & Clinics, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).
The cartilage repair/regeneration market size for hyaline applications is projected to widen further as surgeons prioritize tissue-specific products that enhance integration. Meanwhile, niche elastic-cartilage reconstruction for ear and nasal defects creates incremental volume, diversifying revenue streams across smaller sub-segments.
Cell-based solutions captured 61.72% revenue in 2025 through clinical superiority in pain reduction and tissue restoration, as evidenced by meta-analysis reporting standardized mean differences of -1.27 in pain scores. However, cell-free implants should post 14.21% CAGR through 2031 on the strength of off-the-shelf availability and lower cost.
Premium products such as MACI generated USD 46.3 million in Q1 2025 sales, reflecting commercial traction in the United States. Conversely, CARTIHEAL Agili-C offers a cell-free scaffold that reduced total knee arthroplasty risk by 87% at four years. Healthy rivalry between personalized and ready-to-use solutions ensures a balanced growth outlook across the cartilage repair/regeneration market.
Asia-Pacific is projected to deliver a 15.02% CAGR, buoyed by infrastructure investment and rising disposable incomes. China’s procurement reforms, which halved implant prices, improve affordability even as regulatory pathways tighten. Japan leverages universal coverage for advanced therapies, whereas South Korea attracts inbound medical tourists for stem-cell knee repairs priced at USD 5,000-15,000. India’s expanding middle class gradually lifts procedure counts despite reimbursement gaps.
Europe sustains innovation momentum through EMA’s advanced therapy framework and EUR 11.3 million ENCANTO funding. Middle East & Africa and South America remain nascent yet compelling as economic development enlarges insured populations, positioning them as long-range demand reservoirs for the cartilage repair/regeneration market.
Global Cartilage Repair/Regeneration Market Trends and Insights
Escalating Global Incidence of Osteoarthritis and Traumatic Cartilage Lesions
Surging osteoarthritis prevalence, which climbed 132.2% between 1990 and 2022, now affects 7.96% of the global population and drives sustained demand for restorative surgery. Adult cases aged 30-44 exceeded 32.97 million in 2022, underscoring a shift toward younger patients seeking durable repair solutions. Chondral defects afflict 36% of athletes’ knees, creating a sizable cohort that prefers definitive intervention over symptom management. The widening patient base ensures that the cartilage repair/regeneration market remains on an expanding trajectory through the decade.Surge in Outpatient Minimally Invasive Orthopedic Procedures
Same-day discharge for joint surgeries in the United States rose from less than 1% in 2017 to 30.5% in 2023, demonstrating payer and provider confidence in ambulatory pathways. FDA clearance of MACI Arthro in August 2024 validated arthroscopic delivery of autologous chondrocyte implants, further normalizing outpatient treatment. Ambulatory surgical centers benefit most, displaying a 15.07% CAGR through 2030 as they combine cost savings with better patient convenience. This procedural migration underpins broader adoption across the cartilage repair/regeneration market.High Procedure and Implant Costs Limiting Uptake
Stem-cell knee therapy costs range between USD 5,000 and USD 15,000 in South Korea, restricting adoption beyond affluent or insured patients. China’s volume-based procurement cut total hip arthroplasty prices by 50.1%, highlighting intense cost pressure that could spill over to cartilage technologies. Blue Cross payers in the United States mandate stringent criteria for autologous chondrocyte implantation, illustrating reimbursement hurdles. These economic constraints slow penetration in price-sensitive regions, tempering cartilage repair/regeneration market growth.Other drivers and restraints analyzed in the detailed report include:
- Breakthroughs in Tissue-Engineered Scaffolds and Cell-Based Implants
- Increasing Participation in High-Impact and Recreational Sports
- Lengthy and Complex Regulatory Approval Pathways
Segment Analysis
Hyaline tissue held 65.52% of revenue in 2025, confirming its central role in load-bearing joints most vulnerable to degeneration. Bilayer atelocollagen scaffolds now replicate hyaline morphology more reliably, improving long-term outlook for patients. Fibrocartilage, driven by meniscal repair needs, is projected to expand at 14.02% CAGR, supported by advances in collagen-based hydrogels that recruit endogenous stem cells.The cartilage repair/regeneration market size for hyaline applications is projected to widen further as surgeons prioritize tissue-specific products that enhance integration. Meanwhile, niche elastic-cartilage reconstruction for ear and nasal defects creates incremental volume, diversifying revenue streams across smaller sub-segments.
Cell-based solutions captured 61.72% revenue in 2025 through clinical superiority in pain reduction and tissue restoration, as evidenced by meta-analysis reporting standardized mean differences of -1.27 in pain scores. However, cell-free implants should post 14.21% CAGR through 2031 on the strength of off-the-shelf availability and lower cost.
Premium products such as MACI generated USD 46.3 million in Q1 2025 sales, reflecting commercial traction in the United States. Conversely, CARTIHEAL Agili-C offers a cell-free scaffold that reduced total knee arthroplasty risk by 87% at four years. Healthy rivalry between personalized and ready-to-use solutions ensures a balanced growth outlook across the cartilage repair/regeneration market.
Complete Report Scope:
- By Types of Cartilage
- Hyaline Cartilage
- Fibrocartilage
- Elastic / Other Cartilage
- By Treatment Modality
- Cell-based Therapies
- Non-cell-based / Cell-free Therapies
- By Treatment Type
- Palliative (Debridement, Viscosupplementation)
- Intrinsic Repair Stimulus (ACI, MACI, Micro-fracture)
- By Surgical Technique
- Chondroplasty & Micro-fracture
- Autologous Chondrocyte Implantation (ACI)
- Matrix-induced ACI (MACI)
- Osteochondral Allograft / Juvenile Allograft
- By Application Site
- Knee
- Hip
- Ankle
- Spine
- Other Joints (Shoulder, Elbow, Wrist)
- By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America produced 44.72% of 2025 revenue, underpinned by FDA clearances and consistent private‐payer reimbursement. Vericel, Arthrex, and Stryker dominate surgeon preference, while Johnson & Johnson’s VELYS unicompartmental knee robot received clearance in June 2024, spotlighting ongoing innovation. Growth remains steady as baby-boomer activity levels sustain procedure volumes.Asia-Pacific is projected to deliver a 15.02% CAGR, buoyed by infrastructure investment and rising disposable incomes. China’s procurement reforms, which halved implant prices, improve affordability even as regulatory pathways tighten. Japan leverages universal coverage for advanced therapies, whereas South Korea attracts inbound medical tourists for stem-cell knee repairs priced at USD 5,000-15,000. India’s expanding middle class gradually lifts procedure counts despite reimbursement gaps.
Europe sustains innovation momentum through EMA’s advanced therapy framework and EUR 11.3 million ENCANTO funding. Middle East & Africa and South America remain nascent yet compelling as economic development enlarges insured populations, positioning them as long-range demand reservoirs for the cartilage repair/regeneration market.
List of Companies Covered in this Report:
- Arthrex
- Stryker
- Zimmer Biomet
- Smiths Group
- Johnson & Johnson
- Vericel
- Anika Therapeutics
- B. Braun
- Geistlich Pharma
- CYFUSE Biomedical K.K.
- Conmed
- MEDIPOST
- CartiHeal Ltd.
- Askel Healthcare Oy
- BioTissue
- Collagen Solutions
- Matricel
- Orthocell Ltd.
- Osiris Therapeutics
- Autocart Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Arthrex Inc.
- Stryker
- Zimmer Biomet
- Smith + Nephew
- Johnson & Johnson (DePuy Synthes)
- Vericel Corporation
- Anika Therapeutics Inc.
- B. Braun SE
- Geistlich Pharma AG
- CYFUSE Biomedical K.K.
- Conmed Corporation
- MEDIPOST
- CartiHeal Ltd.
- Askel Healthcare Oy
- BioTissue
- Collagen Solutions PLC
- Matricel GmbH
- Orthocell Ltd.
- Osiris Therapeutics
- Autocart Inc.
